Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.
Future Cardiol. 2024 Apr 25;20(5-6):251-261. doi: 10.1080/14796678.2024.2360818. Epub 2024 Jun 12.
Heart failure (HF) affects more than 60 million individuals globally. Empagliflozin is currently approved for type 2 diabetes and chronic HF. Clinical trials have demonstrated that empagliflozin reduces the composite end point of hospitalizations for HF and mortality and improves the quality of life irrespective of left ventricular ejection fraction. Empagliflozin is a once-daily medication with minimal drug-drug interactions and does not require titration. Empagliflozin causes mild weight loss and does not significantly reduce blood pressure. Empagliflozin acts as an enabler for other HF drugs by reducing the risk of hyperkalemia. Empagliflozin is also beneficial for chronic kidney disease which exists commonly with HF. This review outlines the pharmacokinetics, pharmacodynamics, safety, and efficacy of empagliflozin in HF across various sub-groups and settings.
心力衰竭（HF）影响着全球超过 6000 万人。恩格列净目前被批准用于 2 型糖尿病和慢性 HF。临床试验表明，恩格列净可降低 HF 住院和死亡率的复合终点，并改善生活质量，而不论左心室射血分数如何。恩格列净是一种每日一次的药物，与药物相互作用最小，无需滴定。恩格列净可导致轻微的体重减轻，且不会显著降低血压。恩格列净通过降低高钾血症的风险，成为其他 HF 药物的辅助药物。恩格列净对 HF 常见的慢性肾病也有好处。本综述概述了恩格列净在 HF 各种亚组和环境中的药代动力学、药效学、安全性和疗效。
